Stock Updates

Is this Large Market Cap Stock target price reasonable for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)?

The company in question is, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) currently with a stock price of 95.59 (-0.15% today). The market cap for BioMarin Pharmaceutical Inc. is 16233.09, and is in the sector Healthcare, and Biotechnology industry. The target price for BioMarin Pharmaceutical Inc. is 119.29. Currently BioMarin Pharmaceutical Inc. is trading with a P/E of *TBA, and a forward P/E of *TBA. Average volume for BioMarin Pharmaceutical Inc. is 1898.1 and so far today it is 1082677.

Performance in the last year for BioMarin Pharmaceutical Inc. has been -24.40%. For EPS growth, BioMarin Pharmaceutical Inc. has seen a growth of -17.30%, and is looking to grow in the next year to 73.00%. More long term stats show that EPS growth has been -21.30% over the last five years and could be 25.00% for the next five years. BioMarin Pharmaceutical Inc. has seen sales growth quarter over quarter at 20.00%, with EPS growth quarter over quarter at -409.70%. The 20-day simple moving average is 4.12%, with the 200-day simple moving average coming to 8.56%.

Since the IPO date for BioMarin Pharmaceutical Inc. on the 7/26/1999, BioMarin Pharmaceutical Inc. has seen performance year to date to be -8.75%. With BioMarin Pharmaceutical Inc. trading at 95.59, the dividend yield is *TBA, and the EPS is -3.27.

So could BioMarin Pharmaceutical Inc., be undervalued? Well as said before P/E is *TBA. The PEG is *TBA, P/S is 16.67 and the P/B is at 8.11. The P/cash is 32.25, with P/free cash flow at *TBA.

BioMarin Pharmaceutical Inc. ability to deal with debt shows that the current ratio is 3, and the quick ratio is 2.1. This is with long term debt/equity at 0.34, and total debt/equity at 0.35.

In terms of margins, BioMarin Pharmaceutical Inc. has a gross margin of 82.10%, an operating margin of -65.20% and a profit margin of -54.50%.Payout ratio for BioMarin Pharmaceutical Inc. is *TBA. Return on assets come to -15.10% with return on investment coming to -4.20%.

Insider ownership for BioMarin Pharmaceutical Inc., is at 0.60% and institutional ownership comes to 99.30%. Outstanding shares are at 169.82. While shares float is 169.82. The float short is currently 4.26%, and short ratio is 3.81.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Peter Clarke

Leave a Comment